First-in-Human, Double-Blind, Randomized, Placebo-Controlled Trial of TQ-F3083, a New Dipeptidyl Peptidase-4 Inhibitor, in Healthy Chinese Adults

Background: As a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, TQ-F3083 represents a promising new drug for type 2 diabetes mellitus (T2DM). This phase I, first-in-human study evaluated the tolerability, pharmacokinetics, and pharmacodynamics of TQ-F3083 in healthy Chinese adults. Methods: Sixty h...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jingrui, Zhu, Xiaoxue, Zhang, Hong, Wei, Haijing, Yang, Deming, Xu, Zhongnan, Huo, Dandan, Li, Xiaojiao, Ding, Yanhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339258/
https://www.ncbi.nlm.nih.gov/pubmed/34366847
http://dx.doi.org/10.3389/fphar.2021.689523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339258/
https://www.ncbi.nlm.nih.gov/pubmed/34366847
http://dx.doi.org/10.3389/fphar.2021.689523

Ejemplares similares